Ultragenyx Pharmaceutical (NASDAQ:RARE) Now Covered by Analysts at William Blair

William Blair assumed coverage on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE - Free Report) in a research note issued to investors on Wednesday morning, Marketbeat reports. The firm issued an outperform rating and a $65.00 price objective on the biopharmaceutical company's stock. William Blair also issued estimates for Ultragenyx Pharmaceutical's FY2025 earnings at ($3.48) EPS, FY2026 earnings at ($1.79) EPS, FY2027 earnings at $1.75 EPS and FY2028 earnings at $4.94 EPS.

A number of other research firms also recently weighed in on RARE. Cantor Fitzgerald reissued an "overweight" rating and set a $118.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. Piper Sandler decreased their price target on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating for the company in a research report on Monday, March 17th. Morgan Stanley raised their price target on shares of Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the stock an "overweight" rating in a research report on Friday, May 9th. JPMorgan Chase & Co. raised their price target on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. Finally, HC Wainwright reissued a "buy" rating and set a $95.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. One analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat.com, Ultragenyx Pharmaceutical presently has a consensus rating of "Moderate Buy" and a consensus price target of $89.31.

Ultragenyx Pharmaceutical Price Performance

NASDAQ RARE traded down $1.16 on Wednesday, reaching $33.87. The company had a trading volume of 1,631,431 shares, compared to its average volume of 841,561. The firm has a market capitalization of $3.20 billion, a PE ratio of -5.34 and a beta of 0.34. Ultragenyx Pharmaceutical has a 1 year low of $29.59 and a 1 year high of $60.37. The firm has a 50-day moving average of $35.61 and a 200-day moving average of $40.72.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.03). The company had revenue of $139.29 million during the quarter, compared to analysts' expectations of $145.98 million. Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The firm's revenue was up 28.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($2.03) EPS. As a group, sell-side analysts expect that Ultragenyx Pharmaceutical will post -5.18 EPS for the current fiscal year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 1,785 shares of the firm's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $40.40, for a total value of $72,114.00. Following the sale, the chief financial officer now directly owns 106,169 shares in the company, valued at approximately $4,289,227.60. This trade represents a 1.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider John Richard Pinion sold 14,439 shares of the firm's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $607,881.90. Following the completion of the sale, the insider now owns 107,766 shares in the company, valued at $4,536,948.60. The trade was a 11.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 97,415 shares of company stock worth $4,094,958. 5.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in shares of Ultragenyx Pharmaceutical by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 10,034,862 shares of the biopharmaceutical company's stock valued at $422,167,000 after purchasing an additional 89,389 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Ultragenyx Pharmaceutical by 28.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,218,942 shares of the biopharmaceutical company's stock valued at $116,559,000 after purchasing an additional 706,519 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its stake in shares of Ultragenyx Pharmaceutical by 81.6% during the first quarter. Adage Capital Partners GP L.L.C. now owns 2,149,000 shares of the biopharmaceutical company's stock valued at $77,815,000 after purchasing an additional 965,919 shares in the last quarter. Federated Hermes Inc. raised its stake in shares of Ultragenyx Pharmaceutical by 0.3% during the first quarter. Federated Hermes Inc. now owns 2,055,200 shares of the biopharmaceutical company's stock valued at $74,419,000 after purchasing an additional 5,400 shares in the last quarter. Finally, Deutsche Bank AG raised its stake in shares of Ultragenyx Pharmaceutical by 0.5% during the first quarter. Deutsche Bank AG now owns 1,701,493 shares of the biopharmaceutical company's stock valued at $61,611,000 after purchasing an additional 8,385 shares in the last quarter. 97.67% of the stock is currently owned by institutional investors.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.